Company: PSTV
Filing Date: 2025-04-30
Form Type: 10-K/A
Source: 0000950170-25-061028
Chunk: 13

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-30
Form: 10-K/A
Chunk 13
---
’s stockholders and recommending to the Board appropriate action on any such recommendation; • reviewing the Board committee structure and recommend to the Board changes to such structure; • reviewing and reassessing the adequacy of our Corporate Governance Guidelines and recommending any proposed changes; • overseeing the annual self-evaluations of the Board and Board committees; • reviewing and discussing with management disclosures in our annual proxy statement regarding director independence; and • overseeing succession planning and processes for our Chief Executive Officer. Item 11. Executiv e Compensation. Director Compensation Our Board believes that the level of director compensation should be based on time spent carrying out Board and committee responsibilities and be competitive with comparable companies. In addition, the Board believes that a significant portion of director compensation should align director interests with the long-term interests of stockholders. The Board makes changes in its director compensation practices upon the recommendation of the Compensation Committee and following discussion and approval by the Board. Director Compensation Our Board, following the Compensation Committee’s recommendation, approved the 2024 compensation of our non-employee directors, as described below. The compensation level of our non-employee directors is expected to remain the same in 2025.

|                        |     | Annual Service Retainer ($) |        |     | Chairperson Additional Retainer ($) |        |
|:-----------------------|:----|:----------------------------|-------:|:----|:------------------------------------|-------:|
| Board                  |     | $                           | 40,000 |     | $                                   | 37,500 |
| Audit Committee        |     |                             |  7,500 |     |                                     | 27,500 |
| Compensation Committee |     |                             |  5,000 |     |                                     | 15,000 |

| Nominating and Corporate Government Committee |     | 5,000 |     | 10,000 |

On February 22 2024, each non-employee director was awarded a grant of options for 2,250 shares as equity compensation and on September 11, 2024 awarded a grant of options for 3,650 shares as equity compensation. Director Compensation Table The following table sets forth information regarding compensation awarded to, earned by or paid to our non-employee directors who served on our Board during fiscal year 2024:

| Name(1)                      |     | Fees Earned 
 or Paid in  
 Cash        |        |     | Option       
 Awards(2)(3) |       |     | Total |         |
|:-----------------------------|: